Role of antiidiotypic antibodies on the clinical course of idiopathic thrombocytopenic purpura

Mehta, Y.S.; Ghosh, Kanjaksha; Badakere, S S; Pathare, Anil; Mohanty, Dipika

doi:10.1016/s0022-2143(03)00104-5

Cited by 10 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found reports suggesting sequence homologies between the platelet membrane glycoproteins and mitochondrial antigen M2,[11] dengue viral NS1,[12] and human immunodeficiency virus-1 GP41. [13] It may not be out of place to mention here that dengue and other arbovirus infections are very common in India in addition to ubiquitous Ebstein-Barr virus and cytomegalovirus, which are known to cause immune thrombocytopenia by unknown mechanisms. Some of our patients who developed anti-GPIIb/IIIa antibodies had higher levels of GPIIb/IIIa on their platelet surface by flow cytometry.…”

Section: Resultsmentioning

confidence: 99%

Antiplatelet antibodies in cases of Glanzmann′s thrombasthenia with and without a history of multiple platelet transfusion

Ghosh¹,

Kulkarni²,

Shetty³

et al. 2009

Indian J Hum Genet

View full text Add to dashboard Cite

Antiplatelet antibodies are known to be present in a wide spectrum of patients, which include chronic Idiopathic Thrombocytopenic Purpura (ITP), infections, etc., including Glanzmann's thrombasthenia (GT) patients who receive multiple platelet transfusions. The presence of natural antibodies to platelet receptors is not studied in cases of GT. We studied the antiplatelet antibodies in 23 patients with GT, 15 of which had received multiple transfusions and eight that had not received transfusions, along with 50 cases of chronic ITP. The prevalence and specificity of platelet-bound antibodies were detected by inhibition assays using O-group platelets on flow cytometry. The mean antiplatelet antibodies in 15 patients of GT who had not received transfusions and eight patients with multiple transfusions was 8427 + 2131.88 and 9038 + 2856 antibodies/platelet, respectively, while in case of the 50 ITP patients studied, it was 22166 + 5616 antibodies/platelet (Normal Range 1500–3200 antibodies/platelet). We conclude that GT patients who have not received transfusions may develop antiplatelet antibodies to the missing/abnormal receptor. Whether this is due to a molecular mimicry or due to some other mechanism needs to be explored.

show abstract

Section: Resultsmentioning

confidence: 99%

Antiplatelet antibodies in cases of Glanzmann′s thrombasthenia with and without a history of multiple platelet transfusion

Ghosh¹,

Kulkarni²,

Shetty³

et al. 2009

Indian J Hum Genet

View full text Add to dashboard Cite

show abstract

“…All cases had normal antiplatelet antibody , and ferritin levels, and were grouped according to whether they had mild (100–150 × 10 9 /L), moderate (50–100 × 10 9 /L) or severe (<50 × 10 9 /L) thrombocytopenia. A detailed clinical history, including age of onset and type of any bleeding symptoms was recorded for each case, using the World Health Organisation (WHO) bleeding scale (grade 0, no bleeding; grade 1, petechiae; grade 2, mild blood loss; grade 3, gross blood loss; grade 4, debilitating blood loss) to score the severity of bleeding symptoms.…”

Section: Methodsmentioning

confidence: 99%

Congenital macrothrombocytopenia is a heterogeneous disorder in India

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Anti-Id against autoantibodies are described also in other autoimmune diseases, such as systemic lupus erythematosus, myasthenia gravis, Sjorgren’s syndrome, and idiopathic thrombocytopenic purpura (Abdou et al, 1981; Dwyer et al, 1983; Zouali and Eyquem, 1983; Mehta et al, 2003) (Routsias et al, 2002). Their regulatory function has been suggested based on observations that anti-Id are found in healthy individuals and that in patients anti-Id levels are inversely related to disease severity (Williams and Isenberg, 1998; Mehta et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

“…Their regulatory function has been suggested based on observations that anti-Id are found in healthy individuals and that in patients anti-Id levels are inversely related to disease severity (Williams and Isenberg, 1998; Mehta et al, 2003). …”

Section: Introductionmentioning

confidence: 99%

Comparison of three assays for the detection of GAD65Ab-specific anti-idiotypic antibodies

Oak

Radtke

Landin‐Olsson

et al. 2009

Journal of Immunological Methods

View full text Add to dashboard Cite

Anti-idiotypic antibodies (anti-Id) to autoantibodies are present in several autoimmune diseases and are hypothesized to have regulatory function. Recently we reported the presence of anti-Id to a major type 1 diabetes-associated autoantibody (GAD65Ab) in sera of healthy individuals. Our current assay for the detection of GAD65Ab-specific anti-Id requires the initial removal of anti-Id from the sera using immobilized monoclonal GAD65Ab, followed by detection of the now exposed GAD65Ab. However, anti-Id in samples that are GAD65Ab-negative cannot be detected in this assay. Furthermore, we cannot distinguish between serum GAD65Ab and the monoclonal GAD65Ab used in the absorption of anti-Id. In this study we evaluated two novel detection assays for GAD65Ab-specific anti-Id. The biotin/streptavidin based absorption assay utilizes the strong interaction of biotin and streptavidin to prevent possible leakage of the immobilized antibody. Moreover, this assay format allows to identify the origin of the detected GAD65Ab. The ECL-based assay allows the direct detection of anti-Id independent of the presence of GAD65Ab. We analyzed new-onset type 1 diabetes patients (n=133) and matched healthy controls (n=178) for the presence of GAD65Ab-specific anti-Id using both new detection assays and the original absorption assay. We found that all three assays can distinguish between the type 1 diabetes cohort and the healthy control samples. The biotin/streptavidin assay allowed us to positively exclude the monoclonal GAD65Ab as the source of the detected GAD65Ab. While the original absorption assay showed the highest sensitivity and specificity, the ECL format showed the highest peak signal-to-noise ratio and excellent linear correlation, making this assay our first choice for quantification of anti-Id.

show abstract

Role of antiidiotypic antibodies on the clinical course of idiopathic thrombocytopenic purpura

Cited by 10 publications

References 20 publications

Antiplatelet antibodies in cases of Glanzmann′s thrombasthenia with and without a history of multiple platelet transfusion

Antiplatelet antibodies in cases of Glanzmann′s thrombasthenia with and without a history of multiple platelet transfusion

Congenital macrothrombocytopenia is a heterogeneous disorder in India

Comparison of three assays for the detection of GAD65Ab-specific anti-idiotypic antibodies

Contact Info

Product

Resources

About